Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting heterochromatin eliminates chronic myelomonocytic leukemia malignant stem cells through reactivation of retroelements and immune pathways.
Hidaoui D, Porquet A, Chelbi R, Bohm M, Polyzou A, Alcazer V, Depil S, Imanci A, Morabito M, Renneville A, Selimoglu-Buet D, Thépot S, Itzykson R, Laplane L, Droin N, Trompouki E, Elvira-Matelot E, Solary E, Porteu F. Hidaoui D, et al. Among authors: thepot s. Commun Biol. 2024 Nov 22;7(1):1555. doi: 10.1038/s42003-024-07214-1. Commun Biol. 2024. PMID: 39578583 Free PMC article.
FLT3 ligand kinetic profile predicts response to treatment in patients with high-risk myelodysplastic syndrome / chronic myelomonocytic leukemia receiving CPX-351: a study from the Groupe Francophone des Myélodysplasies.
Peterlin P, Gaschet J, Turlure P, Gourin MP, Dumas PY, Thepot S, Berceanu A, Park S, Hospital MA, Cluzeau T, Torregrosa-Diaz JM, Drevon L, Sapena R, Chermat F, Ades L, Dimicoli-Salazar S, Jullien M, Fenaux P, Chevallier P. Peterlin P, et al. Among authors: thepot s. Haematologica. 2024 Nov 21. doi: 10.3324/haematol.2024.286025. Online ahead of print. Haematologica. 2024. PMID: 39568426 Free article.
CXCL8 secreted by immature granulocytes inhibits WT hematopoiesis in chronic myelomonocytic leukemia.
Deschamps P, Wacheux M, Gosseye A, Morabito M, Pagès A, Lyne AM, Alfaro A, Rameau P, Imanci A, Chelbi R, Marchand V, Renneville A, Patnaik MM, Lapierre V, Badaoui B, Wagner-Ballon O, Berthon C, Braun T, Willekens C, Itzykson R, Fenaux P, Thépot S, Etienne G, Elvira-Matelot E, Porteu F, Droin N, Perié L, Laplane L, Solary E, Selimoglu-Buet D. Deschamps P, et al. Among authors: thepot s. J Clin Invest. 2024 Sep 17;134(22):e180738. doi: 10.1172/JCI180738. J Clin Invest. 2024. PMID: 39545419 Free PMC article.
Eltrombopag in chronic myelomonocytic leukemia with severe thrombocytopenia. A Groupe Francophone des Myélodysplasies (GFM) study.
Rabian F, Chevret S, Gruson B, Thépot S, Walter-Petrich A, Braun T, Vey N, Torregrosa-Diaz JM, Peterlin P, Toma A, D'Aveni M, Delaunay J, Legros L, Droin N, Chermat F, Lusina D, Adès L, Sapena R, Solary E, Fenaux P, Itzykson R. Rabian F, et al. Among authors: thepot s. Leukemia. 2024 Nov;38(11):2510-2513. doi: 10.1038/s41375-024-02402-8. Epub 2024 Sep 12. Leukemia. 2024. PMID: 39266637 No abstract available.
Long-term outcome after allogeneic stem cell transplantation for GATA2 deficiency: An analysis of 67 adults and children from France and Belgium.
Sicre de Fontbrune F, Chevillon F, Fahd M, Desseaux K, Poiré X, Forcade E, Sterin A, Neven B, Gandemer V, Thepot S, Garnier A, Lioure B, Marcais A, Nguyen-Quoc S, Tavitian S, Vincent L, Donadieu J, Resche Riggon M, Chevret S, Pasquet M, Peffault de Latour R. Sicre de Fontbrune F, et al. Among authors: thepot s. Br J Haematol. 2024 Aug 19. doi: 10.1111/bjh.19691. Online ahead of print. Br J Haematol. 2024. PMID: 39159950
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial.
Díez-Campelo M, López-Cadenas F, Xicoy B, Lumbreras E, González T, Del Rey González M, Sánchez-García J, Coll Jordà R, Slama B, Hernández-Rivas JÁ, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Götze KS, Arar A, Toribio S, Del Cañizo C, Hernández-Rivas JM, Fenaux P. Díez-Campelo M, et al. Among authors: thepot s. Lancet Haematol. 2024 Sep;11(9):e659-e670. doi: 10.1016/S2352-3026(24)00142-X. Epub 2024 Jul 18. Lancet Haematol. 2024. PMID: 39033767 Clinical Trial.
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Sébert M, Freiman L, Chaffaut C, Guerci A, Peterlin P, Thépot S, Beyne-Rauzy O, Park S, Cluzeau T, Chermat F, Fenaux P, Preudhomme C, Clappier E, Chevret S, Adès L, Duployez N, Duchmann M. Sébert M, et al. Among authors: thepot s. Leukemia. 2024 Apr;38(4):918-922. doi: 10.1038/s41375-024-02180-3. Epub 2024 Feb 17. Leukemia. 2024. PMID: 38368440 No abstract available.
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study.
Gabellier L, Peterlin P, Thepot S, Hicheri Y, Paul F, Gallego-Hernanz MP, Bertoli S, Turlure P, Pigneux A, Guieze R, Ochmann M, Malfuson JV, Cluzeau T, Thomas X, Tavernier E, Jourdan E, Bonnet S, Tudesq JJ, Raffoux E. Gabellier L, et al. Among authors: thepot s. Ann Hematol. 2024 Mar;103(3):759-769. doi: 10.1007/s00277-024-05623-0. Epub 2024 Jan 26. Ann Hematol. 2024. PMID: 38273140 Free PMC article.
[Myelodysplastic syndrome : prognostic factors].
Gyan E, Thépot S. Gyan E, et al. Among authors: thepot s. Bull Cancer. 2023 Nov;110(11):1141-1146. doi: 10.1016/j.bulcan.2023.06.008. Epub 2023 Aug 1. Bull Cancer. 2023. PMID: 37537115 Review. French.
79 results